Star Combo Pharma Limited announced the expansion of its manufacturing capabilities at its wholly-owned TGA-licensed nutraceutical manufacturing site at 171 Woodpark Road, Smithfield, New South Wales. The expansion plans will involve upgrading the existing facility and the installation of 13 new production lines. The capital investment of circa $11 million will enable Star Combo to cost effectively address the growing demand in both local and overseas markets for Australian made premium vitamins and dietary supplements. Approximately $5 million will be invested to upgrade the existing manufacturing plant and a further $6 million for the acquisition and installation of additional plant to establish 13 new production lines. The project will commence in September 2020 and will be completed within two years. This investment is the result of extensive due diligence and evaluation of growth options, and is expected to deliver a substantial ROI with a full return on investment within three years of the lines being in production.